₹ 980.55 Cr
0.21%
NIFTY Pharma TRI
INF204KC1089
1000.0
0.0
100
Jitendra Tolani
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
Nippon India Nifty Pharma ETF | 1.61 | 20.6 | - |
Nifty Pharma TRI | 1.87 | 20.92 | 15.42 |
Equity
Debt
Others
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Company | Holdings (%) |
---|---|
SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 22.82 |
DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 10.92 |
CIPLA LIMITED EQ NEW FV RS.2/- | 10.7 |
Dr. Reddys Laboratories Ltd | 9.87 |
LUPIN LIMITED EQ NEW F.V. RS.2/- | 5.92 |
TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.5 |
AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 4.01 |
LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 3.58 |
ALKEM LABORATORIES LIMITED EQ | 3.36 |
GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/- | 3.34 |
Sector | Holdings (%) |
---|---|
Healthcare | 99.83 |
Scheme Name | 5Y (%) |
---|---|
Nippon India Nifty Pharma ETF | 0.0 |
Mirae Asset Hang Seng TECH ETF | 0.0 |
Nippon India ETF Hang Seng BeES | 5.42 |
Mirae Asset NYSE FANG and ETF | 0.0 |
Tata Gold ETF | 0.0 |
LIC MF Gold Exchange Traded Fund | 12.35 |
ICICI Pru Gold ETF | 11.97 |
ABSL Gold ETF | 12.02 |
Axis Gold ETF | 12.04 |
HDFC Gold ETF | 11.9 |